Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib + Docetaxel in KRAS+ NSCLC
NCT00890825Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of selumetinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Apr 2009; status: completed.
02
Drugs
selumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00890825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00890825.